Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is 80% below its 3-year average of 0.03, near the low end of its 3-year range (0.00–0.10).
As of the fiscal period ended Tuesday, June 30, 2026. 81.64% below its 12-month average of 0.03.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
0.03
DEBT TO EQUITY RATIO AVG 3Y
0.03
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-81.64%
CURRENT VS 3Y AVG
-81.88%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-94.81%
vs the sector median at left
MapLight Therapeutics, Inc.
Market Cap
$411.21M
Debt to Equity Ratio
0.01
TTM Avg
0.03
3Y Avg
0.03
5Y Avg
N/A
Market Cap
$411.00M
Debt to Equity Ratio
0.02
TTM Avg
0.03
3Y Avg
0.06
5Y Avg
0.04
Market Cap
$406.58M
Debt to Equity Ratio
0.54
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$416.27M
Debt to Equity Ratio
0.68
TTM Avg
0.68
3Y Avg
1.01
5Y Avg
1.01
Market Cap
$405.74M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$404.24M
Debt to Equity Ratio
0.69
TTM Avg
0.39
3Y Avg
0.28
5Y Avg
0.26
Market Cap
$418.95M
Debt to Equity Ratio
0.15
TTM Avg
1.54
3Y Avg
0.83
5Y Avg
0.58
Market Cap
$419.87M
Debt to Equity Ratio
0.02
TTM Avg
0.04
3Y Avg
0.03
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | $411.21M | 0.01 | 0.03 | 0.03 | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.00M | 0.02 | 0.03 | 0.06 | 0.04 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $406.58M | 0.54 | N/A | N/A | N/A |
| Rezolute, Inc. (RZLT)vs › | $415.98M | 0.01 | 0.01 | 0.02 | 0.10 |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | 0.68 | 0.68 | 1.01 | 1.01 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $405.74M | 0.00 | 0.00 | 0.00 | 0.00 |
| Myriad Genetics, Inc. (MYGN)vs › | $404.24M | 0.69 | 0.39 | 0.28 | 0.26 |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | 0.15 | 1.54 | 0.83 | 0.58 |
| Prothena Corporation plc (PRTA)vs › | $419.87M | 0.02 | 0.04 | 0.03 | 0.04 |
| Neurogene Inc. (NGNE)vs › | $402.17M | 0.04 | 0.04 | 0.06 | 0.06 |
Debt/Equity
0.01
Current Ratio
16.52
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.01 |
| 2025-12-31 | 0.01 |
| 2025-09-30 | 0.03 |
| 2025-06-30 | 0.10 |
| 2025-03-31 | 0.07 |
| 2024-12-31 | 0.06 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.03 |
| 2023-03-31 | 0.00 |
